Skip to content

AMAKEM: what changed

Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.

What changed

AMAKEM

BE 0817.285.772
NACE 86.910, Medical imaging and medical laboratories
fiscal year 2024 against 2025filed annual accounts (NBB)
Net result for the year
-€5,969
2024 · €290,829-€296,798
Equity
€421,110
2024 · €427,079-€5,969
Cash
€416,285
2024 · €523,243-€106,959
Balance sheet total
€421,110
2024 · €527,079-€105,969

Largest movements

2024 to 2025
Assets
  • Cash -€106,959

    down €106,959 (-20.4%), from €523,243 to €416,285

    mainly Other debts (-€100,000) and Net result for the year (-€5,969)

Equity and liabilities
  • Other debts -€100,000

    down €100,000 (-100.0%), from €100,000 to €0

  • Profit (loss) carried forward -€5,969

    down €5,969 (-0.1%), from -€5.1m to -€5.1m

Income statement
  • Gross operating margin -€298,092

    down €298,092, from €289,970 to -€8,122

From the 2024 result to the 2025 result

effect on the result

Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.

Result 2024 €290,829
Gross operating margin -€298,092
Other operating charges -€12
Financial income +€1,308
Financial charges -€2
Result 2025 -€5,969

Cash bridge derived

cash 2024 to 2025

Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.

From operations -€106,959
Investment €0
Financing €0
Cash 2024 €523,243
Net result for the year -€5,969
Receivables within one year -€990
Deferred charges and accrued income -€0
Other debts -€100,000
Cash 2025 €416,285
Every line side by side 30 lines
Line Code 2024 2025 Change %
Total assets 20/58 €527,079 €421,110 -€105,969 -20.1%
Current assets 29/58 €527,079 €421,110 -€105,969 -20.1%
Amounts receivable within one year 40/41 €2,085 €3,075 +€990 +47.5%
Trade receivables 40 €1,247 €1,585 +€338 +27.1%
Other amounts receivable 41 €838 €1,489 +€652 +77.8%
Cash at bank and in hand 54/58 €523,243 €416,285 -€106,959 -20.4%
Deferred charges and accrued income 490/1 €1,751 €1,751 +€0 0.0%
Total equity and liabilities 10/49 €527,079 €421,110 -€105,969 -20.1%
Equity 10/15 €427,079 €421,110 -€5,969 -1.4%
Contributions 10/11 €5,543,680 €5,543,680 = 0.0%
Capital 10 €420,515 €420,515 = 0.0%
Issued capital 100 €420,515 €420,515 = 0.0%
Outside capital 11 €5,123,165 €5,123,165 = 0.0%
Share premium 1100/10 €5,123,165 €5,123,165 = 0.0%
Profit (loss) carried forward 14 -€5,116,601 -€5,122,570 -€5,969 -0.1%
Amounts payable 17/49 €100,000 €0 -€100,000 -100.0%
Amounts payable within one year 42/48 €100,000 €0 -€100,000 -100.0%
Trade debts 44 €0 - =
Suppliers 440/4 €0 - =
Other amounts payable 47/48 €100,000 €0 -€100,000 -100.0%
Other operating charges 640/8 €449 €462 +€12 +2.8%
Gross operating margin 9900 €289,970 -€8,122 -€298,092
Operating profit (loss) 9901 €289,521 -€8,584 -€298,105
Financial income 75/76B €1,460 €2,768 +€1,308 +89.6%
Recurring financial income 75 €1,460 €2,768 +€1,308 +89.6%
Financial charges 65/66B €152 €153 +€2 +1.0%
Recurring financial charges 65 €152 €153 +€2 +1.0%
Profit (loss) for the period before taxes 9903 €290,829 -€5,969 -€296,798
Profit (loss) for the period 9904 €290,829 -€5,969 -€296,798
Profit (loss) for the period to be appropriated 9905 €290,829 -€5,969 -€296,798

Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 30 September 2026 via checked.be.